Literature DB >> 23509365

Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates.

Haesun Park1, Lauren Adamson, Tae Ha, Karl Mullen, Shoko I Hagen, Arys Nogueron, Andrew W Sylwester, Michael K Axthelm, Al Legasse, Michael Piatak, Jeffrey D Lifson, Juliana M McElrath, Louis J Picker, Robert A Seder.   

Abstract

Prime-boost immunization with heterologous vaccines elicits potent cellular immunity. In this study, we assessed the influence of various TLR ligands on SIV Gag-specific T cell immunity and protection following prime-boost immunization. Rhesus macaques (RMs) were primed with SIV Gag protein emulsified in Montanide ISA51 with or without TLR3 (polyinosinic-polycytidylic acid [poly-IC]), TLR4 (monophosphoryl lipid A), TLR7/8 (3M-012), TLR9 (CpG), or TLR3 (poly-IC) combined with TLR7/8 ligands, then boosted with replication defective adenovirus 5 expressing SIV Gag (rAd5-Gag). After priming, RMs that received SIV Gag protein plus poly-IC developed significantly higher frequencies of SIV Gag-specific CD4(+) Th1 responses in blood and bronchoalveolar lavage (BAL) fluid lymphocytes compared with all other adjuvants, and low-level SIV Gag-specific CD8(+) T cell responses. After the rAd5-Gag boost, the magnitude and breadth of SIV Gag-specific CD8(+) T cell responses were significantly increased in RM primed with SIV Gag protein plus poly-IC, with or without the TLR7/8 ligand, or CpG. However, the anamnestic, SIV Gag-specific CD8(+) T cell response to SIVmac251 challenge was not significantly enhanced by SIV Gag protein priming with any of the adjuvants. In contrast, the anamnestic SIV Gag-specific CD4(+) T cell response in BAL was enhanced by SIV Gag protein priming with poly-IC or CpG, which correlated with partial control of early viral replication after SIVmac251 challenge. These results demonstrate that prime-boost vaccination with SIV Gag protein/poly-IC improves magnitude, breadth, and durability of CD4(+) T cell immune responses, which could have a role in the control of SIV viral replication.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23509365      PMCID: PMC3622154          DOI: 10.4049/jimmunol.1202958

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

Review 1.  Unmet needs in modern vaccinology: adjuvants to improve the immune response.

Authors:  Geert Leroux-Roels
Journal:  Vaccine       Date:  2010-08-31       Impact factor: 3.641

2.  Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.

Authors:  Jeremy M Luke; Gregory G Simon; Jonas Söderholm; John S Errett; J Thomas August; Michael Gale; Clague P Hodgson; James A Williams
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

Review 3.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 4.  Novel adjuvants for B cell immune responses.

Authors:  Karin Loré; Gunilla B Karlsson Hedestam
Journal:  Curr Opin HIV AIDS       Date:  2009-09       Impact factor: 4.283

5.  Simian immunodeficiency virus-specific CD4+ T cells from successful vaccinees target the SIV Gag capsid.

Authors:  Juan P Giraldo-Vela; Alex T Bean; Richard Rudersdorf; Lyle T Wallace; John T Loffredo; Priscilla Erickson; Nancy A Wilson; David I Watkins
Journal:  Immunogenetics       Date:  2010-09-02       Impact factor: 2.846

6.  Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.

Authors:  Christopher Sundling; Sijy O'Dell; Iyadh Douagi; Mattias N Forsell; Andreas Mörner; Karin Loré; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

7.  The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity.

Authors:  Jason Z Oh; Ross M Kedl
Journal:  J Immunol       Date:  2010-09-15       Impact factor: 5.422

8.  Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates.

Authors:  Kavita Tewari; Barbara J Flynn; Silvia B Boscardin; Kathrin Kastenmueller; Andres M Salazar; Charles A Anderson; Velmurugan Soundarapandian; Adriana Ahumada; Tibor Keler; Stephen L Hoffman; Michel C Nussenzweig; Ralph M Steinman; Robert A Seder
Journal:  Vaccine       Date:  2010-09-21       Impact factor: 3.641

9.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

Review 10.  Vaccine adjuvants: putting innate immunity to work.

Authors:  Robert L Coffman; Alan Sher; Robert A Seder
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

View more
  29 in total

1.  Big thinking for adjuvants.

Authors:  Eric L Dane; Darrell J Irvine
Journal:  Nat Biotechnol       Date:  2015-11       Impact factor: 54.908

2.  Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

Authors:  Holly E Janes; Kristen W Cohen; Nicole Frahm; Stephen C De Rosa; Brittany Sanchez; John Hural; Craig A Magaret; Shelly Karuna; Carter Bentley; Raphael Gottardo; Greg Finak; Douglas Grove; Mingchao Shen; Barney S Graham; Richard A Koup; Mark J Mulligan; Beryl Koblin; Susan P Buchbinder; Michael C Keefer; Elizabeth Adams; Chuka Anude; Lawrence Corey; Magdalena Sobieszczyk; Scott M Hammer; Peter B Gilbert; M Juliana McElrath
Journal:  J Infect Dis       Date:  2017-05-01       Impact factor: 5.226

3.  Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.

Authors:  Melissa C Hanson; Monica P Crespo; Wuhbet Abraham; Kelly D Moynihan; Gregory L Szeto; Stephanie H Chen; Mariane B Melo; Stefanie Mueller; Darrell J Irvine
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

4.  Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominance.

Authors:  Otto O Yang; Ayub Ali; Noriyuki Kasahara; Emmanuelle Faure-Kumar; Jin Young Bae; Louis J Picker; Haesun Park
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

5.  Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.

Authors:  Joseph R Francica; Daniel E Zak; Caitlyn Linde; Emilio Siena; Carrie Johnson; Michal Juraska; Nicole L Yates; Bronwyn Gunn; Ennio De Gregorio; Barbara J Flynn; Nicholas M Valiante; Padma Malyala; Susan W Barnett; Pampi Sarkar; Manmohan Singh; Siddhartha Jain; Margaret Ackerman; Munir Alam; Guido Ferrari; Andres Salazar; Georgia D Tomaras; Derek T O'Hagan; Alan Aderem; Galit Alter; Robert A Seder
Journal:  Blood Adv       Date:  2017-11-17

6.  A recombinant multi-epitope protein MEP1 elicits efficient long-term immune responses against HIV-1 infection.

Authors:  Yi Yang; Qing Zhu; Weilai Sun; Jingjing Guo; Xiuzhe Ning; Qiao Li; Yan Guo; Junfeng Li; Zhihua Kou; Yusen Zhou
Journal:  Hum Vaccin Immunother       Date:  2017-02-16       Impact factor: 3.452

7.  Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates.

Authors:  Elizabeth A Thompson; Frank Liang; Gustaf Lindgren; Kerrie J Sandgren; Kylie M Quinn; Patricia A Darrah; Richard A Koup; Robert A Seder; Ross M Kedl; Karin Loré
Journal:  J Immunol       Date:  2015-06-29       Impact factor: 5.422

8.  The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice.

Authors:  Hussein Sultan; Takumi Kumai; Toshihiro Nagato; Juan Wu; Andres M Salazar; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2019-01-02       Impact factor: 6.968

9.  Toll-like receptor-3 mediates HIV-1 transactivation via NFκB and JNK pathways and histone acetylation, but prolonged activation suppresses Tat and HIV-1 replication.

Authors:  Biju Bhargavan; Shawna M Woollard; Georgette D Kanmogne
Journal:  Cell Signal       Date:  2015-11-11       Impact factor: 4.315

10.  Coadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity.

Authors:  Kylie M Quinn; Ayako Yamamoto; Andreia Costa; Patricia A Darrah; Ross W B Lindsay; Sonia T Hegde; Teresa R Johnson; Barbara J Flynn; Karin Loré; Robert A Seder
Journal:  J Immunol       Date:  2013-10-02       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.